4.5 Article

Discovery of AZD2716: A Novel Secreted Phospholipase A2 (sPLA2) Inhibitor for the Treatment of Coronary Artery Disease

Journal

ACS MEDICINAL CHEMISTRY LETTERS
Volume 7, Issue 10, Pages 884-889

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.6b00188

Keywords

Secreted phospholipase A(2); sPLA(2); inhibitor; fragment-based drug discovery; fragment screening; atherosclerosis; coronary artery disease

Ask authors/readers for more resources

Expedited structure-based optimization of the initial fragment hit 1 led to the design of (R)-7 (AZD2716) a novel, potent secreted phospholipase A(2) (sPLA(2)) inhibitor with excellent preclinical pharmacokinetic properties across species, clear in vivo efficacy, and minimized safety risk. Based on accumulated profiling data, (R)-7 was selected as a clinical candidate for the treatment of coronary artery disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available